TNFAIP3

Across TCGA pan-cancer cohorts, TNFAIP3 Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated TNFAIP3 data layer compared with 23 for mass-spec protein and 4 for mass-spec protein.

The strongest signal is observed in lung squamous cell carcinoma (LUSC), where higher TNFAIP3 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated TNFAIP3 expression acts as an unfavorable survival marker, although some lineages such as BLCA show a favorable association.

LUSC, COAD, and STAD are the cancer types where TNFAIP3 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUSC	OS	Median	II,III,IV	0.002	0.743	<.001	12	view →
COAD	OS	Median	IV	0.045	0.659	<.001	12	view →
STAD	OS	Median	III,IV	0.003	0.630	<.001	10	view →
SKCM	DFS	Median	All	0.133	0.761	<.001	9	view →
BLCA	OS	Median	II,III,IV	1.000	0.414	.036	8	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

TNFAIP3–LUSC (OS)

Open the LUSC breakdown →